Improved Control of SARS-CoV-2 by Treatment with Nucleocapsid-Specific Monoclonal Antibody

The authors interrogated whether nucleocapsid-specific antibodies could improve protection against SARSCoV-2. They first immunized mice with a nucleocapsid-based vaccine, and then transferred sera from these mice into naïve mice, followed by challenge with SARS-CoV-2.